Home > News > Headline News > Archive

Click on title to read the full article.

GMU researchers hope to customize breast cancer treatment

February 21, 2010

By Jennifer Buske, Washington Post

With the help of grant money, Lance Liotta and Emanuel Petricoin launched a clinical trial last week to study whether medical professionals can customize treatment for patients with metastatic breast cancer by looking at the protein pathways that vary inside each tumor.

Master gene SRC-3 enables breast cancer growth, invasion

February 12, 2010

By Dipali Pathak, Baylor College of Medicine

HOUSTON — The master gene called SRC-3 (steroid receptor coactivator 3) not only enhances estrogen-dependent growth of cancer cells by activating and encouraging the transcription of a genetic message into a protein, it also sends a signal to the cell membrane to promote cell motility or movement – a key element of cancer spread or metastasis, said Baylor College of Medicine researchers and collaborators in a report that appears in the current issue of the journal Molecular Cell.

Another Use for the Cancer Drug Lapatinib

February 9, 2010

By National Cancer Institute

The FDA has approved the use of the drug lapatinib (Tykerb) in combination with letrozole (Femara) to treat postmenopausal women with advanced HER2-positive and hormone receptor (HR)-positive breast cancer.

Xeloda® Adds to Effectiveness of Herceptin® and Taxotere® Regimen for Metastatic Breast Cancer

February 8, 2010

By CancerConsultants.com

Researchers involved in an international multicenter study (CHAT) have reported that the addition of Xeloda® (capecitabine) to Herceptin® (trastuzumab) and Taxotere® (docetaxel) improves response rate and progression-free survival in women with advanced or metastatic HER2-positive breast cancer. However, Xeloda increased toxicities significantly. The details of this study were published early online in the Journal of Clinical Oncology on December 28, 2009.

Trastuzumab combo may help in breast cancer refractory to trastuzumab alone

February 2, 2010

By Reuters Health

Adding lapatinib to trastuzumab may improve progression-free survival in women whose HER2-positive metastatic breast cancer progressed on a previous trastuzumab regimen, according to a paper published online ahead of print in the Journal of Clinical Oncology.

FDA Approves Lapatinib/Letrozole Combination for Advanced Breast Cancer

February 1, 2010

By MedConnect

The US Food and Drug Administration (FDA) has approved an expanded indication for lapatinib (Tykerb, GlaxoSmithKline) in combination with letrozole (Femara, Novartis AG) for the treatment of hormone-positive and human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.